The estimated Net Worth of Renee Selman is at least $91.5 Thousand dollars as of 25 August 2017. Renee Selman owns over 7,250 units of Agile Therapeutics Inc stock worth over $91,480 and over the last 8 years Renee sold AGRX stock worth over $0.
Renee has made over 2 trades of the Agile Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Renee bought 7,250 units of AGRX stock worth $24,288 on 25 August 2017.
The largest trade Renee's ever made was buying 53,333 units of Agile Therapeutics Inc stock on 11 May 2017 worth over $196,265. On average, Renee trades about 12,117 units every 21 days since 2016. As of 25 August 2017 Renee still owns at least 60,583 units of Agile Therapeutics Inc stock.
You can see the complete history of Renee Selman stock trades at the bottom of the page.
Renee's mailing address filed with the SEC is 101, Poor Farm Road, Princeton, Mercer County, New Jersey, 08540, United States.
Over the last 10 years, insiders at Agile Therapeutics Inc have traded over $2,369,944 worth of Agile Therapeutics Inc stock and bought 24,967,253 units worth $79,522,957 . The most active insiders traders include Advisors Llcperceptive Life..., Ab Investor, and Capital Iii Llc Care Capita.... On average, Agile Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $1,032,678. The most recent stock trade was executed by Alfred Altomari on 26 August 2022, trading 50,000 units of AGRX stock currently worth $22,500.
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Agile Therapeutics Inc executives and other stock owners filed with the SEC include: